TRDA - Entrada Therapeutics GAAP EPS of -$0.78 revenue of $18.2M August, 08 2023 10:17 AM Entrada Therapeutics Inc. 2023-08-08 10:17:25 ET Entrada Therapeutics press release ( NASDAQ: TRDA ): Q2 GAAP EPS of -$0.78. Revenue of $18.2M. For further details see: Entrada Therapeutics GAAP EPS of -$0.78, revenue of $18.2M